Antibacterial agents: combination of a rifamycin and a switch region inhibitor
AssigneeRutgers, The State University of New Jersey
InventorRichard H. Ebright
Life of this patent
Estimating the term…
Abstract
It has been determined that co-administration of a rifamycin and a switch-region inhibitor 1) results in synergistic antibacterial effects, enabling efficacy at low, subtoxic doses, and/or 2) results in a low spontaneous resistance frequency, enabling treatment of high-titer infections without treatment failure due to spontaneous resistance. Accordingly, certain embodiments provide composition comprising a rifamycin and a switch region inhibitor, as well as methods of use thereof.
Claims23
A composition comprising a rifamycin and a switch region inhibitor.
A method of treating a bacterial infection in a mammal, reducing the minimum effective dose of at least one of a rifamycin and a switch region inhibitor in a mammal or reducing the spontaneous resistance frequency to at least one of a rifamycin and a switch region inhibitor in a mammal, comprising co-administering 1) a rifamycin and 2) a switch region inhibitor to the mammal.
8-10. (canceled)
A method for inhibiting a bacterial RNA polymerase or for inhibiting the growth of a bacterium comprising contacting the bacterial RNA polymerase or bacterium in vitro or in vivo with 1) a rifamycin and 2) a switch region inhibitor.
(canceled)
21-43. (canceled)
Dependencies are inferred from the claim text.